Searchable abstracts of presentations at key conferences in endocrinology

ea0049s23.2 | Endo Oncology: prolactin, GH and metabolic hormones in oncology pathogenesis (Endorsed by Endocrine Connections) | ECE2017

Is GH a cancer growth factor?

Melmed Shlomo

Acromegaly is associated with increased soft tissue neoplasms, while GH deficient patients are protected from cancer development. Both environmental and age-related signals lead to cellular senescence and cell cycle dysregulation. We have shown that DNA damage-induced cellular senescence increases GH by inducing p53. GH, in turn, suppresses tumor suppressor proteins in both pituitary and nonpituitary cells.These observations led us to propose that intracellular epithelial GH i...

ea0021pl2 | Society for Endocrinology Transatlantic Medal Lecture | SFEBES2009

Pathogenesis of pituitary adenomas

Melmed Shlomo

Hormone-secreting anterior pituitary cells exhibit slow turnover rates. Subsequent postnatal alterations in pituitary size are determined throughout the lifespan by both extrinsic and intrinsic factors. Pituitary tumors account for ~15% of intracranial tumors and arise from differentiated anterior pituitary cell types, and are invariably benign. They may hyper-secrete hormones, or may be clinically silent. Although hypothalamic influences are permissive for adenoma growth, sev...

ea0081ap3 | The Transatlantic Alliance Award Lecture | ECE2022

Growth Hormone: An Adult Endocrine Misnomer

Chesnokova Vera , Zonis Svetlana , Melmed Shlomo

Growth hormone (GH) secreted by the anterior pituitary gland regulates skeletal growth, metabolism and body composition. Although several of these actions are mediated by production of hepatic and local tissue IGF1, GH also acts independent of IGF1. GH is mainly produced from the pituitary as a systemic endocrine hormone, yet is also expressed in local tissues acting in an autocrine/paracrine/intracrine manner. Locally produced non-pituitary GH (npGH) signals the GHR to induce...

ea0063p731 | Pituitary and Neuroendocrinology 2 | ECE2019

Therapeutic decisions in acromegaly according to disease control in patients with acromegaly with or without prior treatment: data from baseline analysis of the SAGIT® validation study

Giustina Andrea , Bronstein Marcello , Chanson Philippe , Petersenn Stephan , Casanueva Felipe , Sert Caroline , Houchard Aude , Melmed Shlomo

Background: The SAGIT® instrument, designed to assist clinicians in staging and managing acromegaly, is undergoing validation. A descriptive analysis of SAGIT Validation study baseline data revealed discrepancies between investigator-evaluated disease-control status, disease activity, hormonal control, and treatment decisions in acromegaly.Objective: To describe the baseline characteristics of patients in the SAGIT® valida...

ea0041gp151 | Pituitary - Clinical | ECE2016

Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post-hoc analysis of a phase 3 trial

Fleseriu Maria , Melmed Shlomo , Mangal Brian , Strasburger Christian J , Biermasz Nienke R

Introduction: Although biochemical markers of acromegaly disease activity, including GH and IGF1, may fluctuate from day-to-day, biochemical treatment response in clinical trials is generally monitored using single-point analyses. Accordingly, longitudinal evaluations may assess patient status more accurately. In a phase 3 trial, oral octreotide capsules (OOC) demonstrated sustained composite endpoint GH and IGF1 response for ≤13 months in 151 patients with acromegaly pr...

ea0090p402 | Pituitary and Neuroendocrinology | ECE2023

Treatment Patterns in Acromegaly: Analysis of Real-World US Insurance Claims from the MarketScan® Database

Brue Thierry , Fleseriu Maria , Barkan Ariel , Duquesne Edouard , Houchard Aude , del Pilar Schneider Maria , Ribeiro-Oliveira Antonio , Melmed Shlomo K.

Background: Medical treatment for acromegaly (characterized by excess growth hormone [GH] production) includes somatostatin receptor ligands (SRLs), dopamine agonists (DAs), and GH receptor antagonists (GHRAs). However, recent real-world United States (US) treatment evaluations are few. We present treatment patterns for patients receiving medications for acromegaly (1/1/2010–31/7/2022).Methods: De-identified data were extracted from MarketScan&...

ea0028s1.2 | Genetic regulation of pituitary tumorigenesis | SFEBES2012

Modelling pituitary tumours in zebrafish

Liu Ning-Ai , Jiang Hong , Ben-Shlomo Anat , Wawrowsky Kolja , Fan Xue-Mo , Lin Shuo , Melmed Shlomo

The pituitary is highly sensitive to cell cycle disruptions. Although CDK gene mutations have not readily been identified in human pituitary tumors, overexpression of cyclins and dysregulation of CDK inhibitors are encountered in pituitary adenomas, indicating the importance of CDK activation for potential therapeutic targeting. However, it is difficult to predict which CDK inhibitor(s) may be effective against particular tumor types in vivo. Therefore, animal models fa...

ea0037ep721 | Pituitary: clinical | ECE2015

Cabergoline is an effective treatment for clinically non-functioning pituitary adenomas

Greenman Yona , Cooper Odelia , Yaish Iris , Robenshtok Eyal , Sagiv Nadav , Jonash-Kimchi Tali , Mallick Jayati , Gertych Arkadiusz , Shimon Ilan , Zvi Ram , Melmed Shlomo , Stern Naftali

As optimal postoperative management of patients with clinically nonfunctioning pituitary adenomas (NFPA) is a matter of debate, the role of dopamine agonist (DA) therapy in this clinical setting was evaluated.Methods: Retrospective analysis of prospectively collected data was conducted at two pituitary referral centrer with different standard practices for post-operative management of NFPA: DA therapy or conservative follow up. Dopamine receptor 2 (D2R) ...

ea0070oc4.6 | Pituitary and Neuroendocrinology | ECE2020

Results from the phase 3, randomized, double-blind, placebo-controlled OPTIMAL study of oral octreotide capsules in adult patients with acromegaly

Samson Susan , Nachtigall Lisa , Fleseriu Maria , Gordon Murray , Ludlam William , Patou Gary , Haviv Asi , Molitch Mark E , Biermasz Nienke , Strasburger Christian J , Kennedy Laurence , Melmed Shlomo

Background: Many patients with acromegaly report limitations of long-acting somatostatin receptor ligand (SRL) injections, including ongoing disease symptoms near cycle-end and injection-site pain. Oral octreotide capsules (OOC) may provide an alternative to monthly injections. The phase 3 CHIASMA OPTIMAL study assessed efficacy and safety of OOC in patients with acromegaly controlled on injectable SRLs.Methods: A multinational, randomized, placebo-contr...

ea0070aep577 | Pituitary and Neuroendocrinology | ECE2020

Biochemical control of most patients reverting to injectable long-acting somatostatin receptor ligands is achieved after one dose: Results from the phase 3, randomized, double blind, placebo-controlled optimal study

Fleseriu Maria , Samson Susan , Nachtigall Lisa , Labadzhyan Artak , Elenkova Atanaska , Molitch Mark E , Ludlam William , Patou Gary , Haviv Asi , Biermasz Nienke , Strasburger Christian J , Kennedy Laurence , Melmed Shlomo

Background: Injectable somatostatin receptor ligands (SRLs) are currently the most widely used therapy for acromegaly. Oral octreotide capsules (OOC) are a potential therapy for acromegaly; the safety and efficacy were evaluated in the CHIASMA OPTIMAL pivotal study (Samson et al. ENDO 2020). As reported, mean IGF-I levels of the OOC group were maintained within normal range at end of treatment in all patients. However, some patients may not respond to OOC treatment (2...